Mergers & Acquisitions

Pharmaceuticals, Drugs, Biotechnology

ConAlliance is specialised in conducting divestiture and acquisition activity within the pharmaceutical and biotechnology industry.

While representing the buy-side, we help pharmaceutical executives on the hunt for new therapies and new customers to drive growth. M&A deals for example, allow companies  diversify product portfolios, secure pipeines of high-quality active pharmaceutical ingredients (API) and generic pharmaceuticals expand into emerging markets, and achieve economies of scale.

When we are engaged by the sell-side, we need to analyze the company, its strengths and weaknesses, the market and competitors, and much more. What is the best time for divestiture with reference to the life-cycle of the pharmaceutical product? Who are the potential buyers? What is the worth of the company and how can sales-revenue be maximized? How can the transaction be secured in terms of liabilities, guarantees and warranties?

Overall Mergers and Acquisitions can provide  excellent possibilities to gain access to new products and markets, new revenue streams and geographic expansion to drive  organic growth. Thus we are bringing two sides together: buyers and sellers of a pharmaceutical company.

At the same time we carry out on ongoing analysis of private European specialty life science companies, in order to advance M&A advisory services for our clients.

ConAlliance offers a holistic advisory service for the pharmaceutical and biotechnologic industry.